Keynote Speakers

Dr. Dong Wang


Dong Wang, PhD
Department of Pharmaceutical Sciences College of Pharmacy University of Nebraska Medical Center Omaha, NE


Dr. Dong Wang is a professor of Pharmaceutical Sciences at the University of Nebraska Medical Center (UNMC). His research primarily focuses on prodrug and medicine development for inflammatory, musculoskeletal and craniofacial diseases. Dr. Wang obtained his PhD in polymer chemistry and physics from Peking University, China. He then joined Prof. Jindřich Kopeček’s laboratory at the University of Utah for 3 years of postdoctoral training in pharmaceutical chemistry. He joined UNMC in early 2005 as a tenure-track assistant professor and was promoted to associate professor with tenure in 2008. In 2014, he was promoted to the rank of full professor. Dr. Wang has published over 100 peer-reviewed papers and numerous conference abstracts. As the lead inventor, Dr. Wang has over 110 patents and patent applications, some of which have been licensed to the industry for further development and commercialization. He is also the co-founder of three start-up companies focusing on the translation and commercialization of drug candidates originating from his laboratory.

Dr. Manoj P. Jadhav

 jadhav,_manoj.jpg Manoj P. Jadhav, PhD, FCP
Founder and CEO
Translational Clinical Pharmacologist
ISHA Therapeutics, LLC
Hillsborough, NJ

Dr. Jadhav is responsible for strategic, scientific planning and business functions for the organization.

Dr. Jadhav brings more than 15 years of experience in academic and industry research, pharmaceutical drug development and regulatory affairs experience in the US, India with small molecules and peptides therapeutics.

Before starting ISHA Therapeutics, he served as the Vice President clinical development and business strategy at CRC Pharma based in Parsippany, New Jersey. He has contributed to several drug development programs for both NCEs and 505(b) (2) across different therapeutics areas. At ISHA Therapeutics, he is leading a robust pipeline of novel repurposed drug developed program for lifestyle and infectious diseases.

He is a trained clinical pharmacologist with extensive experience in planning, designing, execution and interpretation of clinical studies (prospective, retrospective, interventional and observational) in the area of infectious diseases, cancer, cardiovascular diseases. He was part of successful team which developed first Indian liposomal amphotericin B (Fungisome TM) which is launched in Indian market.

Dr. Jadhav has represented the Sponsors at the US-FDA for several formal meetings e.g., pre-IND meetings, at the Division of Anti-infectives, Cardiovascular and Renal products, CNS, Dermatology, Pharmaceutical Quality, Oncology etc.

Dr. Jadhav has over twenty-five peer-reviewed publications, co-edited a book, have made numerous posters and oral presentations internationally.

Dr. Jadhav received his PhD in Pharmaceutics from Bombay College of Pharmacy and KEM Hospital at the University of Mumbai, India and did his Post-doctoral Fellowship at the Colleges of Pharmacy and Medicine Univ. of Florida, Gainesville, Florida. He did his M. Pharmacy from DIPSAR, New Delhi (gold medalist).

Dr. Andre Kalil

andre_kalil_-_infectious_disease_-_2014.jpg Andre C. Kalil, MD, MPH., FACP, FIDSA, FCCM
Professor of Medicine
University of Nebraska Medical Center
Omaha, NE

Dr. Kalil is a physician and Professor of Medicine in the Infectious Diseases Section, Department of Internal Medicine at the University of Nebraska Medical Center in Omaha, Nebraska. 

Dr. Kalil received his M.D. from the Federal University of Pelotas in Brazil and joined the University of Nebraska Medical Center faculty in 2003. He did his Internship and Internal Medicine Residency at the University of Miami/Jackson Memorial Hospital, Miami, Florida, and completed his Infectious Diseases and Critical Care Medicine Fellowships at the Massachusetts General Hospital (Harvard University, Boston, MA) and at the National Institutes of Health (NIH, Bethesda, MD), respectively. 

Dr. Kalil works as an attending clinician and a researcher at the University of Nebraska Medical Center. He is currently the Director of the Transplant Infectious Diseases Program at the University of Nebraska.

Dr. Kalil has received numerous honors and awards, including the 2021 Scientist Laureate Award, the 2014 Distinguished Scientist Award, and the 2012 Clinical Research Award. He is a member of a number of professional organizations, has been a peer-reviewer and associate editor for major medical journals, and has published over three hundred PubMed indexed scientific articles.  

Dr. Tammy Leigh Kielian


Tammy Leigh Kielian PhD
Choudari Kommineni, DVM, PhD Professor of Pathology
University of Nebraska Medical Center
Omaha, NE

My laboratory has a long-standing interest in studying the pathogenesis and immune responses elicited by Staphylococcus aureus (S. aureus). To this end, we have developed mouse models of biofilm infection on catheters, orthopedic implants, and cranial bone flaps that accurately mimic the attributes of biofilm infections in humans. Our laboratory was the first to propose that S. aureus biofilms actively elicit an anti-inflammatory immune signature to explain, in part, why biofilm infections persist in an immune competent host. This is achieved by the preferential recruitment of granulocytic-myeloid-derived suppressor cells (G-MDSCs) in addition to polarizing macrophage infiltrates towards an anti-inflammatory phenotype. Ongoing studies are to identify the mechanisms responsible for skewing the host innate immune response to an anti-inflammatory state following S. aureus biofilm infection and how this may be targeted to facilitate bacterial clearance. Emerging areas of interest include immunometabolism and how S. aureus biofilm-leukocyte metabolic crosstalk influences the epigenetic landscape of leukocytes to promote their anti-inflammatory attributes.

Dr. James J. Moon


James J. Moon, PhD
J. G. Searle Professor
Department of Pharmaceutical Sciences
Department of Biomedical Engineering
Department of Chemical Engineering
BioInterfaces Institute
University of Michigan
Ann Arbor, MI

My research group aims to develop novel therapeutics at the interface of immunology, engineering, and pharmaceutical sciences. Specifically, we are developing drug delivery systems designed to enhance delivery of antigen and adjuvant to lymphoid organs and manipulate immune functions in the context of vaccines and immunotherapies against cancer, infectious pathogens, and autoimmune disorders. Our work focusing on the development of nanotechnologies for vaccination and immunotherapy has been published in Nature Materials, Nature Nanotechnology, Nature Medicine, Nature Reviews Materials, Nature Biomedical Engineering, Nature Communications, PNAS, ACS Nano, Sci Transl Med, and Science Advances. Our work has also led to 18 U.S. issued or pending patent applications as well as 3 startup biotech companies.